Active, not recruitingPhase 2NCT06057571
Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor
Studying Cholangiocarcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- TransThera Sciences (Nanjing), Inc.
- Intervention
- TT-00420 (tinengotinib)(drug)
- Enrollment
- 50 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2025
Study locations (28)
- Anhui Provincial Hospital, Hefei, Anhui, China
- Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
- Fujian Cancer Hospital, Fuzhou, Fujian, China
- Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
- Shenzhen Qianhai Shekou Free Trade Zone hospital, Shenzhen, Guangdong, China
- The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
- Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
- The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
- Henan Cancer Hospital, Zhengzhou, Henan, China
- Hubei Cancer Hospital, Wuhan, Hubei, China
- Zhongnan hospital of Wuhan University, Wuhan, Hubei, China
- Hunan Cancer Hospital, Changsha, Hunan, China
- Hunan Provincial People's Hospital, Changsha, Hunan, China
- Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
- Jilin Cancer Hospital, Changchun, Jilin, China
- +13 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06057571 on ClinicalTrials.govOther trials for Cholangiocarcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07478523FAPI-PET Value for the Initial Screening of Pancreatic and Biliary CancersUniversity Hospital, Bordeaux
- RECRUITINGNANCT07476651Scout Dose of Resin MicrospheresSeoul National University Hospital
- RECRUITINGPHASE2NCT06728410A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or RearrangementMehmet Akce
- RECRUITINGPHASE2NCT07201519Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion ChemotherapyMichael J Cavnar, MD
- RECRUITINGPHASE2NCT07223307REGULUS: MRI-guided Adaptive SABR for Liver CancersStanford University
- RECRUITINGPHASE2NCT07260175Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 CholangiocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- RECRUITINGNANCT06735560Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NENNantes University Hospital
- RECRUITINGNANCT07263217Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver InjurySecond Affiliated Hospital, School of Medicine, Zhejiang University